| Literature DB >> 18354269 |
Mahdi Shabani1, Hossein Asgarian-Omran, Hossein Asgarian Omran, Mahmood Jeddi-Tehrani, Parvaneh Vossough, Mohammad Faranoush, Ramazan A Sharifian, Gholam R Toughe, Mahin Kordmahin, Jalal Khoshnoodi, Azam Roohi, Narjes Tavoosi, Hakan Mellstedt, Hodjatallah Rabbani, Fazel Shokri.
Abstract
Receptor tyrosine kinases (RTKs) are a group of enzymes involved in a variety of physiological and pathological processes. The human Ror1 is a member of the RTK family with unknown ligand and biological function. Overexpression of Ror1 has recently been reported in B-cell chronic lymphocytic leukemia. The aim of this study was to explore the expression profile of Ror1 in acute lymphoblastic leukemia (ALL) cells. Therefore, leukemic cells were isolated from the bone marrow and/or peripheral blood (PB) of 57 ALL patients. Immunophenotyping was performed by flow cytometry and mRNA expression was detected by RT-PCR. Overexpression of Ror1 mRNA was detected in 23 of 57 (40%) ALL patients. A similar expression pattern was observed in ALL cell lines, with 4 of 12 (33%) being positive. Stimulation of normal PB mononuclear cells with pokeweed mitogen and phorbol myristate acetate induced substantially higher Ror1 mRNA expression compared to unstimulated cultured cells. There has been neither a significant association between Ror1 expression and the immunophenotypic profile of the leukemic cells, nor with other clinical or hematological features of the patients. In conclusion, our findings propose Ror1 as a new tumor-associated antigen and a potential tool for targeted immunotherapy and monitoring of minimal residual disease in ALL. (c) 2008 S. Karger AG, Basel.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18354269 DOI: 10.1159/000121405
Source DB: PubMed Journal: Tumour Biol ISSN: 1010-4283